| Literature DB >> 23143228 |
Alice Brockington1, Ke Ning, Paul R Heath, Elizabeth Wood, Janine Kirby, Nicolò Fusi, Neil Lawrence, Stephen B Wharton, Paul G Ince, Pamela J Shaw.
Abstract
A consistent clinical feature of amyotrophic lateral sclerosis (ALS) is the sparing of eye movements and the function of external sphincters, with corresponding preservation of motor neurons in the brainstem oculomotor nuclei, and of Onuf's nucleus in the sacral spinal cord. Studying the differences in properties of neurons that are vulnerable and resistant to the disease process in ALS may provide insights into the mechanisms of neuronal degeneration, and identify targets for therapeutic manipulation. We used microarray analysis to determine the differences in gene expression between oculomotor and spinal motor neurons, isolated by laser capture microdissection from the midbrain and spinal cord of neurologically normal human controls. We compared these to transcriptional profiles of oculomotor nuclei and spinal cord from rat and mouse, obtained from the GEO omnibus database. We show that oculomotor neurons have a distinct transcriptional profile, with significant differential expression of 1,757 named genes (q < 0.001). Differentially expressed genes are enriched for the functional categories of synaptic transmission, ubiquitin-dependent proteolysis, mitochondrial function, transcriptional regulation, immune system functions, and the extracellular matrix. Marked differences are seen, across the three species, in genes with a function in synaptic transmission, including several glutamate and GABA receptor subunits. Using patch clamp recording in acute spinal and brainstem slices, we show that resistant oculomotor neurons show a reduced AMPA-mediated inward calcium current, and a higher GABA-mediated chloride current, than vulnerable spinal motor neurons. The findings suggest that reduced susceptibility to excitotoxicity, mediated in part through enhanced GABAergic transmission, is an important determinant of the relative resistance of oculomotor neurons to degeneration in ALS.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23143228 PMCID: PMC3535376 DOI: 10.1007/s00401-012-1058-5
Source DB: PubMed Journal: Acta Neuropathol ISSN: 0001-6322 Impact factor: 17.088
Characteristics of cases
| Case number | Sex | Age at death | Cause of death | Postmortem delay time (h) |
|---|---|---|---|---|
| 1 | M | 64 | Ischaemic heart disease | 12 |
| 2 | M | 64 | Empyema | 30 |
| 3 | F | 59 | Pneumonia | 5 |
| 4 | M | 67 | Hepatocellular carcinoma | 63 |
Numbers of differentially expressed probe sets and PPLR values at different thresholds of q
|
| Upregulated in oculomotor neurons | Upregulated in spinal motor neurons | ||
|---|---|---|---|---|
| No. of probe sets | PPLR values | No. of probe sets | PPLR values | |
| 1.0e−5 | 957 | <7.66e−5 | 209 | <1.17e−4 |
| 1.0e−4 | 1,417 | <0.00060 | 265 | <0.000899 |
| 1.0e−3 | 2,196 | <0.0059 | 340 | <0.011 |
Fig. 1Covariance matrix for the gene expression dataset, evaluated using only the top 100 differentially expressed genes. The samples on both axes are ordered according to the tissue type. The two visible blocks correspond to the two groups, indicating that the most differentially expressed genes are able to capture the difference between oculomotor and spinal cord samples. Each square in the plot shows the correlation between each pair of samples. Warm colours correspond to a high positive correlation, while cold colours correspond to a high negative correlation
Fig. 2Numbers of significantly differentially expressed genes assigned to enriched gene ontology terms. The 20 most enriched KEGG pathways and GO terms in the categories of biological process and cell component are shown. Redundant terms were removed for clarity. a Genes upregulated in oculomotor neurons (q value for enrichment <0.05). Group 1 synaptic function, Group 2 ubiquitin-mediated proteolysis, Group 3 oxidative phosphorylation and mitochondrial function, Group 4 other. b Genes upregulated in spinal motor neurons (q value for enrichment <0.005). Group 1 skeletal development, Group 2 embryonic pattern formation, Group 3 immune system processes, Group 4 the extracellular matrix, Group 5 cell adhesion, Group 6 regulation of transcription, Group 7 other
Gene ontology enrichment analysis
| Gene ontology term | Count |
|
| Fold enriched | |
|---|---|---|---|---|---|
|
| |||||
| 1. Synaptic function | GO:0045202—synapse | 79 | 2.60E−14 | 1.32E−10 | 2.50 |
| GO:0008021—synaptic vesicle | 25 | 1.91E−08 | 2.42E−05 | 3.70 | |
| GO:0007268—synaptic transmission | 57 | 1.98E−07 | 0.00012 | 2.07 | |
| GO:0045211—postsynaptic membrane | 27 | 0.000125 | 0.015 | 2.25 | |
| GO:0019717—synaptosome | 20 | 0.00013 | 0.015 | 2.65 | |
| GO:0001505—regulation of neurotransmitter levels | 18 | 9.25E−05 | 0.012 | 2.90 | |
| 2. Ubiquitin-dependent proteolysis | GO:0019941—modification-dependent protein catabolic process | 94 | 4.57E−08 | 3.86E−05 | 1.77 |
| hsa04120: ubiquitin-mediated proteolysis | 25 | 0.00048 | 0.043 | 2.13 | |
| 3. Mitochondrial function | hsa00190: oxidative phosphorylation | 31 | 2.85E−07 | 0.00014 | 2.78 |
| GO:0005746—mitochondrial respiratory chain | 18 | 2.94E−05 | 0.0055 | 3.16 | |
| GO:0005739—mitochondrion | 135 | 4.15E−05 | 0.0075 | 1.40 | |
| GO:0031966—mitochondrial membrane | 59 | 8.51E−05 | 0.012 | 1.68 | |
| GO:0022900—electron transport chain | 25 | 9.91E−05 | 0.013 | 2.37 | |
| GO:0030964—NADH dehydrogenase complex | 13 | 0.00020 | 0.020 | 3.48 | |
| 4. Other | hsa05012: Parkinson’s disease | 30 | 6.85E−07 | 0.00031 | 2.73 |
| GO:0031982—vesicle | 97 | 1.39E−06 | 0.00050 | 1.63 | |
| GO:0005794—Golgi apparatus | 117 | 4.68E−06 | 0.0013 | 1.51 | |
| GO:0043005—neuron projection | 57 | 5.05E−06 | 0.0013 | 1.87 | |
| hsa05010: Alzheimer’s disease | 33 | 5.14E−06 | 0.0013 | 2.36 | |
| hsa05016: Huntington’s disease | 34 | 1.68E−05 | 0.0034 | 2.20 | |
|
| |||||
| 1. Skeletal system | GO:0001501—skeletal system development | 33 | 1.09E−16 | 3.17E−13 | 6.30 |
| GO:0048704—embryonic skeletal system morphogenesis | 12 | 1.65E−09 | 6.01E−07 | 12.83 | |
| GO:0001649—osteoblast differentiation | 8 | 4.69E−06 | 0.00031 | 11.61 | |
| 2. Ant/post specification | GO:0009952—anterior/posterior pattern formation | 21 | 1.14E−13 | 1.66E−10 | 9.14 |
| GO:0007389—pattern specification process | 26 | 1.62E−12 | 1.57E−09 | 5.93 | |
| 3. Immune response | GO:0006955—immune response | 36 | 1.97E−09 | 6.37E−07 | 3.18 |
| GO:0046649—lymphocyte activation | 18 | 2.76E−08 | 7.31E−06 | 5.51 | |
| GO:0042110—T cell activation | 14 | 1.39E−07 | 2.18E−05 | 6.77 | |
| GO:0009611—response to wounding | 28 | 1.52E−07 | 2.21E−05 | 3.22 | |
| GO:0002684—positive regulation of immune system process | 16 | 8.57E−06 | 0.000509 | 4.10 | |
| GO:0002520—immune system development | 18 | 2.88E−06 | 0.000215 | 3.97 | |
| GO:0006954—inflammatory response | 18 | 2.46E−05 | 0.00116 | 3.37 | |
| 4. Extracellular matrix | GO:0031012—extracellular matrix | 22 | 2.42E−07 | 3.36E−05 | 3.86 |
| GO:0005581—collagen | 7 | 2.00E−05 | 0.000971 | 12.12 | |
| 5. Cell adhesion | GO:0007155—cell adhesion | 31 | 1.21E−06 | 0.000113 | 2.70 |
| GO:0010810—regulation of cell-substrate adhesion | 8 | 8.79E−06 | 0.000512 | 10.60 | |
| 6. Transcription | GO:0045893—positive regulation of transcription, DNA-dependent | 23 | 1.15E−05 | 0.000598 | 2.94 |
| GO:0051254—positive regulation of RNA metabolic process | 23 | 1.32E−05 | 0.000663 | 2.91 | |
| 7. Other | GO:0001568—blood vessel development | 17 | 2.68E−06 | 0.000205 | 4.23 |
| GO:0042127—regulation of cell proliferation | 31 | 1.26E−05 | 0.000644 | 2.40 | |
The 20 most enriched KEGG pathways and gene ontology terms in the categories of biological process and cell component are shown for each motor neuron subtype. Redundant terms were removed for clarity. P value and q value apply to the fold enrichment
Upregulated glutamate receptor subunits and transporters in human oculomotor neurons
| Gene name | Symbol | Probe id | Fold change | PPLR value |
|
|---|---|---|---|---|---|
| Glutamate receptor, ionotropic, AMPA 1 | GLUR1 | 209793_at | 4.82 | 3.49E−15 | 0 |
| 211520_at | 3.20 | 5.60E−06 | 6.59E−07 | ||
| Glutamate receptor, ionotropic, AMPA 2 | GLUR2 | 205358_at | 2.31 | 1.14E−05 | 1.36E−06 |
| 236538_at | 3.31 | 0.002008 | 0.00031 | ||
| Glutamate receptor, ionotropic, kainate 2 | GRIK2 | 213845_at | 5.34 | 5.09E−07 | 4.74E−08 |
| Glutamate receptor, metabotropic 3 | GRM3 | 205814_at | 2.00 | 3.58E−08 | 3.42E−09 |
| Glutamate receptor, metabotropic 7 | GRM7 | 207548_at | 2.50 | 2.30E−06 | 2.72E−07 |
| Glutamate receptor interacting protein 1 | GRIP1 | 235957_at | 2.57 | 6.37E−06 | 7.33E−07 |
| Glutamate receptor interacting protein 2 | GRIP2 | 216481_at | 3.80 | 3.19E−09 | 2.23E−10 |
Upregulated GABA receptor subunits and genes in human oculomotor neurons
| Gene name | Symbol | Probe id | Fold change | PPLR value |
|
|---|---|---|---|---|---|
| Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | GABRA1 | 244118_at | 7.56 | 1.16E−07 | 1.08E−08 |
| Gamma-aminobutyric acid (GABA) A receptor, beta 1 | GABRB1 | 207010_at | 5.21 | 5.35E−08 | 4.57E−09 |
| Gamma-aminobutyric acid (GABA) A receptor, beta 2 | GABRB2 | 155712 _at | 8.76 | 3.78E−20 | 0 |
| 242344_at | 9.21 | 2.61E−05 | 3.21E−06 | ||
| Gamma-aminobutyric acid (GABA) A receptor, epsilon | GABRE | 204537_at | 8.18 | 1.54E−08 | 1.62E−09 |
| Gamma-aminobutyric acid (GABA) A receptor, gamma 1 | GABRG1 | 241805_at | 2.79 | 7.27E−05 | 9.25E−06 |
| Gamma-aminobutyric acid (GABA) receptor, theta | GABRQ | 238123_at | 26.3 | 1.13E−08 | 9.84E−10 |
| Gamma-aminobutyric acid (GABA) B receptor, 2 | GABBR2 | 209990_at | 3.10 | 4.93E−09 | 4.30E−10 |
| 211679_at | 2.33 | 4.83E−06 | 5.75E−07 |
Fig. 3Concentration of GABRA1 relative to β-actin in laser-captured motor oculomotor and spinal motor neurons determined by QPCR (2 cases, n = 6 replicates). Error bars represent SEM
Significantly upregulated glutamate and GABA receptor subunits and genes in mouse and rat oculomotor nucleus
| Gene name | Symbol | Mouse | Rat | ||||
|---|---|---|---|---|---|---|---|
| Probe id | Fold change |
| Probe id | Fold change |
| ||
| Glutamate receptor, ionotropic, AMPA 1 | GLUR1 | 1435239_at | 2.49 | 0.0024 | 1371013_at | 2.05 | 4.79E−06 |
| 1448972_at | 1.83 | 0.0379 | |||||
| Glutamate receptor, ionotropic, AMPA 2 | GLUR2 | 1387171_at | 2.19 | 4.86E−09 | |||
| 1368401_at | 2.02 | 4.23E−08 | |||||
| Glutamate receptor, metabotropic 7 | GRM7 | 1369781_at | 1.29 | 0.0011 | |||
| Glutamate receptor interacting protein 1 | GRIP1 | 1376988_at | 1.48 | 0.0101 | |||
| Glutamate receptor interacting protein 2 | GRIP2 | 1387954_at | 1.29 | 0.0011 | |||
| 1388016_at | 4.95 | 2.38E−06 | |||||
| Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | GABRA1 | 1421281_at | 8.24 | 1.98E−04 | |||
| 1436889_at | 5.62 | 1.85E−05 | |||||
| Gamma-aminobutyric acid (GABA) A receptor, beta 1 | GABRB1 | 1369904_at | 2.30 | 3.82E−04 | |||
| 1369371_at | 1.96 | 1.42E−08 | |||||
| 1388030_at | 1.71 | 5.67E−04 | |||||
| 1388039_at | 1.42 | 9.54E−07 | |||||
| 1375720_at | 1.39 | 6.49E−07 | |||||
| Gamma-aminobutyric acid (GABA) A receptor, beta 2 | GABRB2 | 1450319_at | 2.39 | 0.0059 | 1369818_at | 2.51 | 1.93E−06 |
| 1387383_at | 1.64 | 3.11E−05 | |||||
| 1368952_at | 1.38 | 0.00285 | |||||
| Gamma-aminobutyric acid (GABA) A receptor, epsilon | GABRE | 1388049_at | 1.84 | 3.19E−05 | |||
| Gamma-aminobutyric acid (GABA) A receptor, gamma 1 | GABRG1 | 1387706_at | 1.25 | 0.0300 | |||
| Gamma-aminobutyric acid (GABA) receptor, theta | GABRQ | 1387706_at | 1.25 | 0.0300 | |||
| Gamma-aminobutyric acid (GABA) B receptor, 2 | GABBR2 | 1370701_at | 1.63 | 0.0279 | |||
All GABA and glutamate receptor subunits differentially expressed in human oculomotor and spinal motor neurones are included in the table, and data from rat and mouse oculomotor nucleus versus spinal cord shown, where significant differential expression was found
Fig. 4a and b Concentration–response relation for AMPA-induced whole-cell currents in lumbar spinal cord and oculomotor neurons. Currents were recorded in 20 mM extracellular Na+ at −60 mV, in response to AMPA concentrations ranging from 5 μM to 5 mM. a Representative current traces elicited by AMPA. b Each point represents mean ± SEM from three cells (*P < 0.05, **P < 0.01, Student’s t test). EC50 values estimated from fits to pooled data were 118.6 μM for lumbar spinal cord motor neurons and 123.2 μM for oculomotor neurons. c Whole-cell currents recorded in Na+-free extracellular solution containing 50 mM Ca2+ at −60 mV in lumbar spinal cord and oculomotor neurons, evoked by AMPA 100 μM (n = 6). Columns represent the peak amplitudes of agonist-induced whole-cell currents (mean ± SEM, **P < 0.001, P < 0.05, Student’s t test). d and e Concentration–response relation for kainate-induced whole-cell currents in lumbar spinal cord and oculomotor neurons. Currents were recorded in 20 mM extracellular Na+ at −60 mV, in response to kainate concentrations ranging from 50 μM to 50 mM. d Representative current traces elicited by kainate. e Each point represents mean ± SEM from three cells (*P < 0.05, **P < 0.01, Student’s t test). EC50 values estimated from fits to pooled data were 1.12 mM for lumbar spinal cord motor neurons and 1.26 mM for oculomotor motor neurons, respectively. f Whole-cell currents recorded in Na+-free extracellular solution containing 50 mM Ca2+ at −60 mV in lumbar spinal cord and oculomotor neurons, evoked by kainate 1 mM (n = 6). Columns represent the peak amplitudes of agonist-induced whole-cell currents (mean ± SEM, **P < 0.001, P < 0.05, Student’s t test)
Fig. 5a and b Concentration–response relation for GABA-induced whole-cell currents in lumbar spinal cord and oculomotor motor neurons. Currents were recorded at −60 mV, in response to GABA concentrations ranging from 0.1 mM to 100 mM. Each point represents mean ± SEM from three cells (*P < 0.05, Student’s t test). EC50 values estimated from fits to pooled data were 6.1 mM for lumbar spinal cord motor neurons and 5.7 mM for oculomotor motor neurons, respectively. c GABA-induced whole-cell currents in lumbar spinal cord and oculomotor neurons. Whole-cell currents evoked by 6 mM GABA were recorded at −60 mV. Columns represent the peak amplitudes of GABA-induced whole-cell currents (mean ± SEM, *P < 0.05, n = 6, Student’s t test)